Advertisement

Hemobilia after CT-guided radiofrequency ablation of liver tumors: frequency, risk factors, and clinical significance

  • Mei-Fang Hsieh
  • Chia-Bang Chen
  • Yao-Li Chen
  • Chen-Te Chou
Article
  • 145 Downloads

Abstract

Purpose

The purpose of the study is to evaluate the frequency, risk factors, and clinical significance of hemobilia after percutaneous computed tomography (CT)-guided radiofrequency ablation (RFA) of liver tumors.

Materials and methods

From January 2013 to September 2016, 195 patients received 267 sessions of CT-guided RFA for liver tumors at our institution. The CT images during and immediately after the RFA were retrospectively reviewed. The frequency of hemobilia development and clinical outcome of patients with hemobilia were studied. Risk factors were identified by comparison between the hemobilia and non-hemobilia groups using univariate and multivariate analysis. The clinical courses of patients with hemobilia were also reviewed.

Results

The frequency of CT detected hemobilia after RFA was 8.2% (22/267). The majority of the clinical courses were self-limited. Univariate analysis showed that the tumor numbers (p = 0.015), the central type puncture track (p < 0.001), the length of the puncture track (p = 0.033), and the platelet count (p = 0.026) were significantly associated with the development of hemobilia. Multivariate analysis demonstrated that the central type puncture track (p < 0.024) and the platelet count (p = 0.023) were significant independent risk factors.

Conclusion

Detection of hemobilia on CT images immediately after percutaneous RFA for liver tumors was not rare. Low platelet count and central type puncture track are independent risk factors. In most cases, hemobilia presented as a minor complication with favorable prognosis.

Keywords

Hemobilia CT-guided radiofrequency ablation Hepatocellular carcinoma Liver tumors Complication 

Notes

Compliance with ethical standards

Conflict of interest

All author have no conflict of interest.

Ethical approval

The study was approved by the IRB board of Changhua Christian Hospital.

References

  1. 1.
    Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022.  https://doi.org/10.1002/hep.24199 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Omata M, Lesmana LA, Tateishi R, et al. (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4(2):439–474.  https://doi.org/10.1007/s12072-010-9165-7 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Tateishi R, Shiina S, Teratani T, et al. (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103(6):1201–1209.  https://doi.org/10.1002/cncr.20892 CrossRefPubMedGoogle Scholar
  4. 4.
    Meloni MF, Andreano A, Laeseke PF, et al. (2009) Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation-intermediate and long-term survival rates. Radiology 253(3):861–869.  https://doi.org/10.1148/radiol.2533081968 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Shady W, Petre EN, Gonen M, et al. (2016) Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes—a 10-year experience at a single center. Radiology 278(2):601–611.  https://doi.org/10.1148/radiol.2015142489 CrossRefPubMedGoogle Scholar
  6. 6.
    Solbiati L, Ahmed M, Cova L, et al. (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265(3):958–968.  https://doi.org/10.1148/radiol.12111851 CrossRefPubMedGoogle Scholar
  7. 7.
    Goto E, Tateishi R, Shiina S, et al. (2010) Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. J Clin Gastroenterol 44(5):374–380.  https://doi.org/10.1097/MCG.0b013e3181b7ed76 PubMedCrossRefGoogle Scholar
  8. 8.
    Rhim H, Lim HK, Kim YS, Choi D, Lee KT (2007) Hemobilia after radiofrequency ablation of hepatocellular carcinoma. Abdom Imaging 32(6):719–724.  https://doi.org/10.1007/s00261-006-9158-0 CrossRefPubMedGoogle Scholar
  9. 9.
    Akahane M, Koga H, Kato N, et al. (2005) Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management. Radiographics 25(Suppl 1):S57–S68.  https://doi.org/10.1148/rg.25si055505 CrossRefPubMedGoogle Scholar
  10. 10.
    Curley SA, Marra P, Beaty K, et al. (2004) Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 239(4):450–458CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Takaki H, Yamakado K, Nakatsuka A, et al. (2013) Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions: single-center experience. AJR 200(3):658–664.  https://doi.org/10.2214/AJR.12.8691 CrossRefPubMedGoogle Scholar
  12. 12.
    Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K (2011) Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol 21(12):2584–2596.  https://doi.org/10.1007/s00330-011-2222-3 CrossRefPubMedGoogle Scholar
  13. 13.
    Kim SH, Lim HK, Choi D, et al. (2004) Changes in bile ducts after radiofrequency ablation of hepatocellular carcinoma: frequency and clinical significance. AJR 183(6):1611–1617.  https://doi.org/10.2214/ajr.183.6.01831611 CrossRefPubMedGoogle Scholar
  14. 14.
    Chang IS, Rhim H, Kim SH, et al. (2010) Biloma formation after radiofrequency ablation of hepatocellular carcinoma: incidence, imaging features, and clinical significance. AJR 195(5):1131–1136.  https://doi.org/10.2214/AJR.09.3946 CrossRefPubMedGoogle Scholar
  15. 15.
    Feng W, Yue D, ZaiMing L, et al. (2016) Iatrogenic hemobilia: imaging features and management with transcatheter arterial embolization in 30 patients. Diagn Interv Radiol 22(4):371–377.  https://doi.org/10.5152/dir.2016.15295 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lencioni R, Cioni D, Crocetti L, et al. (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234(3):961–967.  https://doi.org/10.1148/radiol.2343040350 CrossRefPubMedGoogle Scholar
  17. 17.
    Murugesan SD, Sathyanesan J, Lakshmanan A, et al. (2014) Massive hemobilia: a diagnostic and therapeutic challenge. World J Surg 38(7):1755–1762.  https://doi.org/10.1007/s00268-013-2435-5 CrossRefPubMedGoogle Scholar
  18. 18.
    Lee LH, Hwang JI, Cheng YC, et al. (2017) Comparable outcomes of ultrasound versus computed tomography in the guidance of radiofrequency ablation for hepatocellular carcinoma. PLoS ONE 12(1):e0169655.  https://doi.org/10.1371/journal.pone.0169655 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ahmed M, Solbiati L, Brace CL, et al. (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. Radiology 273(1):241–260.  https://doi.org/10.1148/radiol.14132958 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Khalilzadeh O, Baerlocher MO, Shyn PB, et al. (2017) Proposal of a new adverse event classification by the society of interventional radiology standards of practice committee. JVIR 28(10):1432–1437.  https://doi.org/10.1016/j.jvir.2017.06.019 CrossRefPubMedGoogle Scholar
  21. 21.
    Enne M, Pacheco-Moreira LF, Cerqueira A, et al. (2004) Fatal hemobilia after radiofrequency thermal ablation for hepatocellular carcinoma. Surgery 135(4):460–461CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Mei-Fang Hsieh
    • 1
  • Chia-Bang Chen
    • 1
  • Yao-Li Chen
    • 2
    • 3
  • Chen-Te Chou
    • 1
    • 3
    • 4
    • 5
  1. 1.Department of RadiologyChanghua Christian HospitalChanghua CityTaiwan
  2. 2.Transplant Medicine and Surgery Research CentreChanghua Christian HospitalChanghua CityTaiwan
  3. 3.School of MedicineKaohsiung Medical UniversityKaohsiung CityTaiwan
  4. 4.Department of Biomedical Imaging and Radiological SciencesNational Yang-Ming Medical UniversityTaipei CityTaiwan
  5. 5.Department of Molecular Biotechnology, College of Biotechnology and BioresourcesDayeh UniversityChanghua CityTaiwan

Personalised recommendations